ArticleObesity surgery2026
Early Adjuvant Treatment with Semaglutide After Sleeve Gastrectomy in Patients with Class II-III Obesity: A Prospective Non-Randomized Controlled Study.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundWeight management remains a significant challenge for patients with class II-III obesity, even after metabolic bariatric surgery (MBS). This study aimed to investigate the association between early, short-term adjunctive semaglutide therapy and postoperative weight-loss outcomes after laparoscopic sleeve gastrectomy (LSG) in patients with class II-III obesity.
methodsIn this prospective, non-randomized controlled clinical study, patients with class II-III obesity, defined as a body mass index (BMI) ≥ 35 kg/m² scheduled for LSG were enrolled. Semaglutide was administered as adjunctive therapy in the treatment group from 1 to 6 months postoperatively, while the control group received LSG alone. The primary outcome was the percentage of total weight loss (%TWL) at 12 months after surgery. The main secondary outcomes included the percentage of excess weight loss (%EWL) at 12 months, the %TWL and %EWL at 6 months, the distributions of %TWL and %EWL, and metabolic parameters. Exploratory analyses were also performed for body composition parameters.
resultsA total of 103 participants were included in the study, including 48 in the treatment group and 55 in the control group. At 12 months postoperatively, patients in the treatment group showed significantly greater weight loss than the control group, as reflected by a larger %TWL (-35.14 ± 6.88% vs. -30.73 ± 6.91%, P = 0.002) and a higher %EWL (86.42 ± 19.94% vs. 76.87 ± 22.95%, P = 0.026). Similarly, at 6 months postoperatively, %TWL was significantly greater in the treatment group (-29.74 ± 5.38% vs. -26.32 ± 4.10%, P < 0.001), whereas no significant between-group difference in %EWL was observed at 6 months. In addition, the distributions of %TWL and %EWL were more favorable in the treatment group. These results were generally consistent after propensity score adjustment for baseline confounders, although the between-group difference in %EWL distribution was not significant. Both groups showed comparable improvements in metabolic indicators from baseline. Exploratory analyses further showed a greater increase in lean body mass percentage and a greater reduction in visceral fat area in the treatment group, although these body composition findings should be interpreted cautiously.
conclusionThis non-randomized, single-center study indicates that, among patients with a BMI ≥ 35 kg/m
Indexed as
Identifiers
42174244What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.